Insights and challenges in tuberculosis vaccine development by McShane, H

Tuberculosis vaccines: beyond bacille Calmette–Guérin by McShane, H

Human and Bovine Tuberculosis by McShane, H

Improving tuberculosis vaccine trial efficiency: a tough nut to crack by McShane, H

Revaccination with BCG: does it work? by McShane, H

Vaccines for tuberculosis by McShane, H

Editorial commentary: Understanding BCG is the key to improving it by McShane, H

Tuberculosis vaccines: Beyond bacilli Calmette-Guérin by McShane, H

Controlled human infection models: is it really feasible to give people tuberculosis? by McShane, H

Understanding BCG is the key to improving it. by McShane, H

Why don’t we have an effective tuberculosis vaccine yet? by Davenne, T, McShane, H

Challenges in developing a controlled human tuberculosis challenge model by Jackson, S, McShane, H

The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy by Vermaak, S, Sampson, S, McShane, H

Current approaches toward identifying a correlate of immune protection from tuberculosis by Satti, I, McShane, H

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. by McShane, H, Williams, A

Tuberculosis vaccines: Progress and challenges by Checkley, A, McShane, H

Local pulmonary immunological biomarkers in tuberculosis by Morrison, H, McShane, H

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data by McShane, H, Williams, A

Towards new TB vaccines by Brazier, B, McShane, H

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long? by Dockrell, HM, McShane, H